

MEA Gene Therapy Market - Industry Trends and Forecast to 2030

Market Report | 2023-03-01 | 130 pages | Data Bridge Market Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Corporate Users License \$4200.00

Report description:

Middle East and Africa gene therapy market is projected to register a CAGR of 18.3% from 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Middle East and Africa Gene Therapy Market, By Vector Type (Viral Vector and Non-viral Vector), Method (Ex-vivo and In-vivo), Application (Oncological Disorders, Cardiovascular Diseases, Infectious Diseases, Rare Diseases, Neurological Disorders, and Other Diseases), End User (Cancer Institutes, Hospitals, Research institutes, and Others), Country (South Africa and Rest of Middle East and Africa) Industry Trends and Forecast to 2030

Some of the major factors contributing to the growth of the gene therapy market are:

- Rising demand of personalized medicine
- Rising prevalence of genetic disorders
- Novel approaches of gene therapy

Market Players:

The key market players for Middle East and Africa gene therapy market are listed below:

- Amgen, Inc.
- AnGes, Inc
- Biogen
- Bristol Myers Squibb Company
- CHIESI Farmaceutici S.p.A.
- Janssen Pharmaceuticals, Inc.
- Novartis AG

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

Table of Contents:

| | |
|--|----|
| TABLE OF CONTENTS | |
| 1 INTRODUCTION | 20 |
| 1.1 OBJECTIVES OF THE STUDY | 20 |
| 1.2 MARKET DEFINITION | 20 |
| 1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA GENE THERAPY MARKET | 20 |
| 1.4 CURRENCY AND PRICING | 22 |
| 1.5 LIMITATIONS | 22 |
| 1.6 MARKETS COVERED | 22 |
| 2 MARKET SEGMENTATION | 24 |
| 2.1 MARKETS COVERED | 24 |
| 2.2 GEOGRAPHICAL SCOPE | 25 |
| 2.3 YEARS CONSIDERED FOR THE STUDY | 26 |
| 2.4 DBMR TRIPOD DATA VALIDATION MODEL | 27 |
| 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS | 30 |
| 2.6 MULTIVARIATE MODELLING | 31 |
| 2.7 MARKET END USER COVERAGE GRID | 31 |
| 2.8 PRODUCT LIFELINE CURVE | 32 |
| 2.9 DBMR MARKET POSITION GRID | 33 |
| 2.10 VENDOR SHARE ANALYSIS | 34 |
| 2.11 SECONDARY SOURCES | 35 |
| 2.12 ASSUMPTIONS | 35 |
| 3 EXECUTIVE SUMMARY | 36 |
| 4 PREMIUM INSIGHTS | 39 |
| 4.1 PESTEL ANALYSIS | 40 |
| 4.2 PORTER FIVE ANALYSIS | 41 |
| 5 UPDATE ON GERMLINE GENE THERAPY | 42 |
| 5.1 GERMLINE GENE THERAPY | 42 |
| 6 MIDDLE EAST & AFRICA GENE THERAPY MARKET, MO | 43 |
| 6.1 DRIVERS | 45 |
| 6.1.1 NOVEL APPROACHES TO GENE THERAPY | 45 |
| 6.1.2 INCREASING PREVALENCE OF GENETIC DISORDERS | 45 |
| 6.1.3 THE GROWING INVESTMENT BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES | 46 |
| 6.1.4 GROWING DEMAND FOR PERSONALIZED MEDICINE | 47 |
| 6.2 RESTRAINTS | 47 |
| 6.2.1 HIGH COST OF GENE THERAPY | 47 |
| 6.2.2 ETHICAL AND SAFETY CONCERNS | 48 |
| 6.2.3 COMPLEXITY OF GENE THERAPY | 48 |
| 6.3 OPPORTUNITIES | 49 |
| 6.3.1 RISE IN STRATEGIC ACQUISITION AND PARTNERSHIP AMONG ORGANIZATIONS | 49 |
| 6.3.2 RISING APPROVAL FOR GENE THERAPY PRODUCTS | 49 |
| 6.4 CHALLENGES | 50 |
| 6.4.1 STRINGENT REGULATIONS FOR GENE THERAPY PRODUCTS | 50 |
| 6.4.2 LONG-TERM SAFETY AND EFFICACY | 50 |
| 7 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY VECTOR TYPE | 51 |
| 7.1 OVERVIEW | 52 |
| 7.2 VIRAL VECTOR | 55 |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

| | | |
|--------|---|----|
| 7.2.1 | ADENOVIRUS | 56 |
| 7.2.2 | RETROVIRUS | 56 |
| 7.2.3 | LENTIVIRUS | 56 |
| 7.2.4 | ADENO-ASSOCIATED VIRUS | 56 |
| 7.2.5 | VACCINIA VIRUS | 56 |
| 7.2.6 | HERPES SIMPLEX VIRUS | 56 |
| 7.2.7 | OTHERS | 56 |
| 7.3 | NON-VIRAL VECTOR | 56 |
| 7.3.1 | LIPOFECTION | 57 |
| 7.3.2 | INJECTION OF NAKED DNA | 57 |
| 8 | MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY METHOD | 58 |
| 8.1 | OVERVIEW | 59 |
| 8.2 | EX-VIVO | 62 |
| 8.3 | IN-VIVO | 62 |
| 9 | MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY APPLICATION | 64 |
| 9.1 | OVERVIEW | 65 |
| 9.2 | ONCOLOGICAL DISORDERS | 68 |
| 9.3 | CARDIOVASCULAR DISEASES | 68 |
| 9.4 | INFECTIOUS DISEASES | 69 |
| 9.5 | RARE DISEASES | 70 |
| 9.6 | NUEROLOGICAL DISORDERS | 71 |
| 9.7 | OTHER DISEASES | 72 |
| 10 | MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY END USER | 73 |
| 10.1 | OVERVIEW | 74 |
| 10.2 | CANCER INSTITUTES | 77 |
| 10.3 | HOSPITALS | 77 |
| 10.4 | RESEARCH INSTITUTES | 78 |
| 10.5 | OTHERS | 79 |
| 11 | MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY REGION | 80 |
| 11.1 | MIDDLE EAST AND AFRICA | 81 |
| 11.1.1 | SOUTH AFRICA | 87 |
| 11.1.2 | REST OF MIDDLE EAST AND AFRICA | 89 |
| 12 | MIDDLE EAST & AFRICA GENE THERAPY MARKET, COMPANY LANDSCAPE | 90 |
| 12.1 | COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA | 90 |
| 13 | COMPANY PROFILES | 91 |
| 13.1 | BIOGEN | 91 |
| 13.1.1 | COMPANY SNAPSHOT | 91 |
| 13.1.2 | REVENUE ANALYSIS | 91 |
| 13.1.3 | COMPANY SHARE ANALYSIS | 92 |
| 13.1.4 | SWOT ANALYSIS | 92 |
| 13.1.5 | PRODUCT PORTFOLIO | 93 |
| 13.1.6 | RECENT DEVELOPMENT | 93 |
| 13.2 | KITE PHARMA | 94 |
| 13.2.1 | COMPANY SNAPSHOT | 94 |
| 13.2.2 | REVENUE ANALYSIS | 94 |
| 13.2.3 | COMPANY SHARE ANALYSIS | 95 |
| 13.2.4 | SWOT ANALYSIS | 95 |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

| | | |
|---------|-------------------------------|-----|
| 13.2.5 | PRODUCT PORTFOLIO | 96 |
| 13.2.6 | RECENT DEVELOPMENT | 96 |
| 13.3 | NOVARTIS AG | 97 |
| 13.3.1 | COMPANY SNAPSHOT | 97 |
| 13.3.2 | REVENUE ANALYSIS | 97 |
| 13.3.3 | COMPANY SHARE ANALYSIS | 98 |
| 13.3.4 | SWOT ANALYSIS | 98 |
| 13.3.5 | PRODUCT PORTFOLIO | 99 |
| 13.3.6 | RECENT DEVELOPMENTS | 99 |
| 13.4 | BRISTOL-MYERS SQUIBB COMPANY. | 100 |
| 13.4.1 | COMPANY SNAPSHOT | 100 |
| 13.4.2 | REVENUE ANALYSIS | 100 |
| 13.4.3 | COMPANY SHARE ANALYSIS | 101 |
| 13.4.4 | SWOT ANALYSIS | 101 |
| 13.4.5 | PRODUCT PORTFOLIO | 102 |
| 13.4.6 | RECENT DEVELOPMENT | 102 |
| 13.5 | OXFORD BIOMEDICA | 103 |
| 13.5.1 | COMPANY SNAPSHOT | 103 |
| 13.5.2 | REVENUE ANALYSIS | 103 |
| 13.5.3 | COMPANY SHARE ANALYSIS | 104 |
| 13.5.4 | SWOT ANALYSIS | 104 |
| 13.5.5 | PRODUCT PORTFOLIO | 105 |
| 13.5.6 | RECENT DEVELOPMENTS | 105 |
| 13.6 | AGC BIOLOGICS | 106 |
| 13.6.1 | COMPANY SNAPSHOT | 106 |
| 13.6.2 | PRODUCT PORTFOLIO | 106 |
| 13.6.3 | RECENT DEVELOPMENT | 106 |
| 13.7 | ANGES, INC | 107 |
| 13.7.1 | COMPANY SNAPSHOT | 107 |
| 13.7.2 | REVENUE ANALYSIS | 107 |
| 13.7.3 | PRODUCT PORTFOLIO | 108 |
| 13.7.4 | RECENT DEVELOPMENT | 108 |
| 13.8 | AMGEN INC. | 109 |
| 13.8.1 | COMPANY SNAPSHOT | 109 |
| 13.8.2 | REVENUE ANALYSIS | 109 |
| 13.8.3 | PRODUCT PORTFOLIO | 110 |
| 13.8.4 | RECENT DEVELOPMENT | 110 |
| 13.9 | BLUEBIRD BIO, INC. | 111 |
| 13.9.1 | COMPANY SNAPSHOT | 111 |
| 13.9.2 | PRODUCT PORTFOLIO | 111 |
| 13.9.3 | RECENT DEVELOPMENT | 111 |
| 13.10 | CHIESI FARMACEUTICI S.P.A | 112 |
| 13.10.1 | COMPANY SNAPSHOT | 112 |
| 13.10.2 | REVENUE ANALYSIS | 112 |
| 13.10.3 | PRODUCT PORTFOLIO | 113 |
| 13.10.4 | RECENT DEVELOPMENT | 113 |
| 13.11 | DENDREON PHARMACEUTICALS LLC | 114 |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

| | | |
|---------|-----------------------------------|-----|
| 13.11.1 | COMPANY SNAPSHOT | 114 |
| 13.11.2 | PRODUCT PORTFOLIO | 114 |
| 13.11.3 | RECENT DEVELOPMENT | 114 |
| 13.12 | ENZYVANT THERAPEUTICS GMBH | 115 |
| 13.12.1 | COMPANY SNAPSHOT | 115 |
| 13.12.2 | RODUCT PORTFOLIO | 115 |
| 13.12.3 | RECENT DEVELOPMENT | 115 |
| 13.13 | FERRING B.V. | 116 |
| 13.13.1 | COMPANY SNAPSHOT | 116 |
| 13.13.2 | PRODUCT PORTFOLIO | 116 |
| 13.13.3 | RECENT DEVELOPMENT | 116 |
| 13.14 | JANSSEN PHARMACEUTICALS, INC. | 117 |
| 13.14.1 | COMPANY SNAPSHOT | 117 |
| 13.14.2 | PRODUCT PORTFOLIO | 117 |
| 13.14.3 | RECENT DEVELOPMENT | 117 |
| 13.15 | MALLINCKRODT. | 118 |
| 13.15.1 | COMPANY SNAPSHOT | 118 |
| 13.15.2 | REVENUE ANALYSIS | 118 |
| 13.15.3 | PRODUCT PORTFOLIO | 119 |
| 13.15.4 | RECENT DEVELOPMENT | 119 |
| 13.16 | ORCHARD THERAPEUTICS PLC. | 120 |
| 13.16.1 | COMPANY SNAPSHOT | 120 |
| 13.16.2 | REVENUE ANALYSIS | 120 |
| 13.16.3 | PRODUCT PORTFOLIO | 121 |
| 13.16.4 | RECENT DEVELOPMENT | 121 |
| 13.17 | SHANGHAI SUNWAY BIOTECH CO., LTD. | 122 |
| 13.17.1 | COMPANY SNAPSHOT | 122 |
| 13.17.2 | PRODUCT PORTFOLIO | 122 |
| 13.17.3 | RECENT DEVELOPMENT | 122 |
| 13.18 | SIBONO | 123 |
| 13.18.1 | COMPANY SNAPSHOT | 123 |
| 13.18.2 | PRODUCT PORTFOLIO | 123 |
| 13.18.3 | RECENT DEVELOPMENT | 123 |
| 13.19 | SPARK THERAPEUTICS, INC. | 124 |
| 13.19.1 | COMPANY SNAPSHOT | 124 |
| 13.19.2 | PRODUCT PORTFOLIO | 124 |
| 13.19.3 | RECENT DEVELOPMENT | 124 |
| 13.20 | UNIQURE NV. | 125 |
| 13.20.1 | COMPANY SNAPSHOT | 125 |
| 13.20.2 | REVENUE ANALYSIS | 125 |
| 13.20.3 | PRODUCT PORTFOLIO | 126 |
| 13.20.4 | RECENT DEVELOPMENT | 126 |
| 14 | QUESTIONNAIRE | 127 |
| 15 | RELATED REPORTS | 130 |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

MEA Gene Therapy Market - Industry Trends and Forecast to 2030

Market Report | 2023-03-01 | 130 pages | Data Bridge Market Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

| Select license | License | Price |
|----------------|-------------------------|-----------|
| | Single User License | \$3500.00 |
| | Corporate Users License | \$4200.00 |
| | | VAT |
| | | Total |

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

| | | | |
|---------------|----------------------|-------------------------------|---|
| Email* | <input type="text"/> | Phone* | <input type="text"/> |
| First Name* | <input type="text"/> | Last Name* | <input type="text"/> |
| Job title* | <input type="text"/> | | |
| Company Name* | <input type="text"/> | EU Vat / Tax ID / NIP number* | <input type="text"/> |
| Address* | <input type="text"/> | City* | <input type="text"/> |
| Zip Code* | <input type="text"/> | Country* | <input type="text"/> |
| | | Date | <input type="text" value="2026-06-09"/> |
| | | Signature | <input type="text"/> |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com